Navigation Links
Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer

TAMPA, Fla., April 23 /PRNewswire/ -- Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients.  Each year, more than 200,000 Americans are diagnosed with lung cancer.

The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy.   The correlation between ERCC1 levels and therapy response was discovered at Moffitt Cancer Center and exclusively licensed to Genzyme Corporation in November of 2007.  Genzyme Genetics, a business unit of Genzyme Corporation, officially launched the ERCC1 Analysis on May 1, 2009.

Several studies(1-6) have shown that evaluating the expression levels of excision repair cross-complementation group 1 (ERCC1) may help physicians identify patients that may benefit from platinum-based chemotherapy - currently considered the standard of care in advanced NSCLC.  Specifically, low expression levels of ERCC1 have been related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.  

"We are very pleased that many medical oncologists have begun utilizing this lung cancer test to better identify chemotherapy for non small cell lung cancer patients," said Jarett Rieger, Director of the Office of Technology Management and Licensing at Moffitt. "This test is an example of personalized medicine emanating from Moffitt Cancer Center, and as a result of our licensing partnership with Genyzme this test can now benefit lung cancer patients."

"The ERCC1 test complements our growing menu of personalized tests that predict response to treatment in NSCLC," said Celeste Chenet-Monte,  Director Marketing, Oncology at Genzyme Genetics. "Other tests on our menu include EGFR and KRAS mutation analysis, ALK gene rearrangements and EGFR amplification, all of which can be used for prediction of response to targeted therapies used to treat patients with advanced NSCLC."  

According to a 5-year retrospective study (n= 389) published in the New England Journal of Medicine, overall survival was significantly longer for patients with ERCC1-negative tumors who had received adjuvant cisplatin chemotherapy when compared to the control group treated by surgery alone (56 months vs 42 months, respectively).  Among patients with ERCC1-positive tumors, there was no significant difference in survival between the adjuvant chemotherapy group and the control group (50 months vs 55 months respectively).  

To learn more about Genzyme Genetics ERCC1 Analysis, please visit the website:

About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center  is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer. Moffitt's sole mission is to contribute to the prevention and cure of cancer.

1) Vilmar A, et al. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer (2008), doi:10.1016/j.lungcan.2008.08.006.

2) Fujii T, et al. ERCC1 predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2007; 08:025.

3) Lord RV, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non small cell lung cancer. Clin Cancer Res 2002; 8:2286—91.

4) Olaussen K, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983–91.

5) Hwang IG, et al. ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery. J Thorac Oncol 2007; 2:S367.

6) Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006; 355:1054-5.

SOURCE Moffitt Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Moffitt Cancer Center Signs Licensing Agreement with Proteacel, LLC
2. MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging
3. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
4. Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
5. Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
6. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
7. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
8. invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial
9. The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer
10. Living longer: Colon cancer patients gain time with radiofrequency ablation treatment
11. Going for gold with a novel interventional radiology treatment for pancreatic cancer
Post Your Comments:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):